Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor


Tytuł :
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
Autorzy :
Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Grasela D; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Gardiner D; Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America.
Bucy RP; Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Vakkalagadda B; Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Lowy I; Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*immunology
HIV Infections/*drug therapy
HIV-1/*immunology
Ipilimumab/*administration & dosage
Viremia/*drug therapy
Adult ; CD4 Lymphocyte Count ; CTLA-4 Antigen/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Female ; HIV Infections/immunology ; HIV Infections/metabolism ; HIV Infections/virology ; Humans ; Ipilimumab/adverse effects ; Ipilimumab/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; RNA, Viral/blood ; Viremia/immunology ; Viremia/metabolism
Czasopismo naukowe
Tytuł :
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Autorzy :
Ramagopal UA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461.
Liu W; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461.; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461.
Garrett-Thomson SC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461.
Bonanno JB; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461.
Yan Q; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461.
Srinivasan M; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063.
Wong SC; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063.
Bell A; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063.
Mankikar S; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063.
Rangan VS; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063.
Deshpande S; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA 94063 alan.korman@bms.com.
Almo SC; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461; alan.korman@bms.com.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2017 May 23; Vol. 114 (21), pp. E4223-E4232. Date of Electronic Publication: 2017 May 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antigen-Antibody Complex/*metabolism
Antineoplastic Agents, Immunological/*pharmacology
Binding Sites, Antibody/*immunology
CTLA-4 Antigen/*antagonists & inhibitors
Ipilimumab/*pharmacology
Melanoma/*drug therapy
Biological Factors/pharmacology ; CTLA-4 Antigen/immunology ; Cell Line ; Crystallography, X-Ray ; HEK293 Cells ; Humans ; Immunotherapy/methods ; Protein Binding ; Protein Structure, Tertiary
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies